Execs expect study to expand market for implantable heart devices

06/15/2009 | Reuters

Medical-device executives are optimistic that the market for cardiac resynchronization therapy devices and other expensive implants could double if the MADIT-CRT study yields positive results. The Boston Scientific-sponsored study aims to show that combining defibrillators with CRT devices could delay the progression of early-stage heart failure. An analyst with FAF Advisors, however, said reimbursement will play a key role in boosting the sales of the combination products.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY